Caricamento...
Sigma ligands, but not N-methyl-d-aspartate antagonists, reduce levodopa-induced dyskinesias
Levodopa (l-DOPA) is the ‘gold standard’ to treat Parkinson's disease. Unfortunately, dyskinesias detract from its efficacy. Current dyskinesia treatments, including amantadine and dextromethorphan, are thought to work via N-methyl-d-aspartate (NMDA) antagonism, but this hypothesis has not been...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2008
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2845294/ https://ncbi.nlm.nih.gov/pubmed/18281903 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/WNR.0b013e3282f3b0d1 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|